Ask a small number of qualified candidates to answer the same evidence request. A suggested starting point is two or three candidates plus the incumbent, where relevant—not an unrestricted supplier directory.
Maintain an evidence register with these fields:
Claim | Legal entity | Facility | Product/route | State | Source | Evidence date | Status | Unresolved question | Owner
Use four statuses: independently verified fact, supplier assertion, buyer assumption, specialist review required. “Not retrieved” should remain unknown, not become either a clean bill of health or an adverse finding.
Supplier due-diligence checklist
| Area | Request and verification task | Decision implication |
|---|---|---|
| Identity and licensing | Match contract entity, dispensing facility, address and relevant licence records. California’s lookup distinguishes pharmacy, sterile-compounding, nonresident sterile-compounding and outsourcing categories. | A familiar trading name is insufficient; assess the actual facility and relevant permission. (pharmacy.ca.gov) |
| Inspection and enforcement | Review FDA records where applicable, state disciplinary records, supplier responses and corrective-action evidence. | FDA’s outsourcing register does not include all state actions; a Form 483 is not a final agency determination of a violation. (fda.gov) |
| Compounding history | Search FDA’s inspections, recalls and other-actions records using the facility and associated names. | Ask a qualified reviewer to assess findings and remediation relevant to the proposed work. (fda.gov) |
| Product identity and handling | Request specimen labels, formulation details where relevant, dosing materials, storage instructions and complaint procedures. | FDA has identified fraudulent labelling, dosing errors and concerns about semaglutide salt forms in unapproved products. (fda.gov) |
| Approved-drug provenance | Ask the responsible trading partner to demonstrate applicable supplier verification, tracing and suspect-product procedures. | FDA identifies these as core DSCSA responsibilities for pharmacies. Determine your clinic’s own role separately. (fda.gov) |
| Shipping and excursions | Request product-specific packaging qualification, shipping rules, excursion assessment, replacement responsibility and complaint escalation. | FDA has reported concerns about compounded injectable GLP-1 products arriving inadequately refrigerated. (fda.gov) |
| Operational capability | Request recent aggregate acceptance, clarification, dispensing and delivery data; capacity assumptions; allocation rules; escalation contacts; and a sample reporting export. | Treat claimed performance as unverified until supported by records or a controlled pilot. |
Do not use an outdated DSCSA deadline as a procurement shortcut. FDA’s August 6, 2026 letter extends specified small-business-dispenser exemptions through November 27, 2027; it does not exempt qualifying organisations from every DSCSA obligation. Have the relevant specialist establish applicability to the actual entity and transaction. (fda.gov)
What should the multi-state coverage matrix contain?
Build one row for each facility × destination state × product route:
- Relevant permission and independently checked source.
- Licence status, expiry and disciplinary-review status.
- Written confirmation that the pharmacy accepts the proposed prescriptions.
- Delivery limitations, operating cutoffs and patient-support availability.
- Confirmed capacity for the intended launch volume.
- Responsible owner and unresolved launch conditions.
Exit test: clinical, legal and operational approvers can distinguish evidence from marketing claims. A “nationwide” statement is not the matrix.
Explore the table row by row
A working view of the research
Identity and licensing
- Request and verification task
- Match contract entity, dispensing facility, address and relevant licence records. California’s lookup distinguishes pharmacy, sterile-compounding, nonresident sterile-compounding and outsourcing categories.
- Decision implication
- A familiar trading name is insufficient; assess the actual facility and relevant permission. (pharmacy.ca.gov)
Sources cited on this page
- pharmacy.ca.gov · Source 1 ↗https://www.pharmacy.ca.gov/about/verify_lic
- fda.gov · Source 2 ↗https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- fda.gov · Source 3 ↗https://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-recalls-and-other-actions
- fda.gov · Source 4 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- fda.gov · Source 5 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/pharmacists-utilize-dscsa-requirements-protect-your-patients
- fda.gov · Source 6 ↗https://www.fda.gov/media/194424/download